ONYVAX GRANTED BROAD US PATENT FOR LEAD PROSTATE
London, UK – 04 December, 2007: Onyvax Limited, the biotechnology
company developing novel cancer therapies, today announced that
it has been issued a broad patent (US Patent No. 7,303,911) that
protects Onycap23, the company's proprietary prostate cancer cell
line. Onycap23 is a key component of Onyvax-P, the company’s
lead product that is designed to stimulate the immune system to
fight prostate cancer that is currently in two Phase IIb clinical
trials. This patent significantly strengthens the company’s
intellectual property position.
Onyvax-P consists of three prostate cancer cell lines, each representative
of a different site or stage of prostate cancer. Using a combination
of cell lines in this way ensures that a broad range of prostate
cancer antigens are presented to the immune system and this decreases
the risks of the tumor being able to mutate and become resistant
to the therapy. Onyvax either owns or has exclusive rights to
use all three prostate cancer cell lines that form the basis of
Onyvax-P. As with all its cell lines, Onyvax has fully tested
Onycap23 for safety and stability and has demonstrated that it
both meets the current regulatory requirements and has the appropriate
robustness for an industrial manufacturing process.
Dr. Anthony Walker, CEO of Onyvax said: "We are pleased
to have been issued this broad patent which further protects the
company’s intellectual property position. The patent protection,
biological nature of Onyvax-P and the ownership of the cell lines
are three substantial barriers to entry for companies wishing
to compete in this field”.
Prostate cancer is one of the most prevalent cancers that affects
the male population. Each year approximately 410,000 patients
are diagnosed with the disease in the seven major markets, of
which 250,000 cases are in the United States alone. The incidence
of progression to HRPC in the seven major markets is over 36,500
patients per annum, with a total patient population of 220,000.
For further information:
Dr Anthony Walker / Robert Johnson
+44 (0)208 682 9494
+44 (0)20 7831 3113
Notes to editors
Onyvax Ltd is a biotechnology company developing novel cancer
therapies that harness the selective power of the immune system
to seek and destroy tumour cells.
Founded in 1998, Onyvax is developing products that use the power
of the immune system to treat prostate and other cancers. Onyvax’s
lead products are based on combinations of inactivated cell lines
that induce immune responses to a broad spectrum of tumour targets.
Onyvax-P, a Cell Vaccine for prostate cancer, is the subject of
two randomized, double blind, placebo controlled Phase IIb clinical
trials, one in Europe, the other in US. For each cancer type,
Onyvax generates banks of proprietary cell lines representative
of different stages of the disease. The vaccines are manufactured
in bulk under standardized conditions.
Onyvax is committed to the commercialization of new therapies
that significantly prolong survival while maintaining a high quality
of life for cancer patients. The Company is based in London and
has collaborations with leading institutions in Europe and the
US. Further information on Onyvax can be found at www.onyvax.com